Imexpharm Corporation reported VND2,205 billion (US$87.3 million) in net revenue for 2024, marking a 10.6% year-on-year increase.

HYTN will endeavour to amend its licenses and/or certificates, establish a stability program, and implement GMP-compliant processes tailored for vape cartridge production.

Imexpharm Corporation has announced its 2024 financial results with net revenue reaching VND2,205 billion, up 10.6 percent year on year, driven by robust growth in ETC channel and high-quality ...

Venus Remedies secures EU GMP renewal from Infarmed, strengthens European market presence: Our Bureau, Bengaluru Wednesday, January 22, 2025, 15:30 Hrs [IST] Venus Remedies has an ...

VANCOUVER, British Columbia, Jan. 21, 2025 (GLOBE NEWSWIRE) -- (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a company specializing in pharmaceutical-grade cannabis manufacturing ...

Pharma major Venus Remedies on Tuesday said it has secured renewal of European Good Manufacturing Practices (EU-GMP) certification by Infarmed, the National Authority of Medicines and Health Products ...

Venus Remedies secures renewed EU GMP certification for its manufacturing facility, enabling expansion in European and global ...

Curaleaf Holdings down 68% in a year, with 66 dispensaries in Florida. Q324 showed in-line results and international growth.

The U.S. Food and Drug Administration (FDA) has been playing catch-up on three long-delayed proposed rules required under the Modernization ...

HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“ HYTN ” or the “Company ”), a pharmaceutical company specializing in pharmaceutical-grade cannabis manufacturing is pleased to announce ...

EQS-News: SynBiotic SE / Key word (s): Mergers & Acquisitions/Strategic Company Decision SYNBIOTIC with four new investments in 2024: Further acquisitions in sight for 2025 10.01.2025 / 11:44 ...